Instrument Inactif

Communiqués Clinigen Group plc

Actions

JCR Pharmaceuticals implements IZCARGO Named Patient Supply Program	28/03/23	AQ
Clinigen : Supplier Code of Conduct 2023	28/03/23	PU
Adragos Pharma acquires Clinigen's development unit, Lamda Laboratories	20/03/23	AQ
Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories	20/03/23	AQ
Clinigen : Global Human Rights & Anti Slavery Policy	10/03/23	PU
Clinigen : Global Anti-Bribery & Corruption Policy	10/03/23	PU
Clinigen : Global Anti-Money Laundering Policy	10/03/23	PU
Clinigen : Global Anti-Trust Policy	10/03/23	PU
Clinigen : Global Health & Safety Policy	10/03/23	PU
Clinigen : Global Freedom to Speak Up Policy	10/03/23	PU
Clinigen : Global Data Protection Policy	10/03/23	PU
Clinigen : Global Diversity, Equity & Inclusion Policy	10/03/23	PU
Clinigen : Global Environmental Policy	10/03/23	PU
Clinigen : Global Human Rights & Anti Slavery Policy	03/02/23	PU
CLINIGEN NOTES RESULTS FROM THE MIROCALS TRIAL INVESTIGATING LOW DOSE PROLEUKIN IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS	09/12/22	AQ
Clinigen : notes results from the MIROCALS trial investigating low dose Proleukin® (aldesleukin) in patients with amyotrophic lateral sclerosis	08/12/22	PU
Clinigen expands US site capacity in response to growing demand for Clinical Supplies Management services	24/05/22	AQ
Clinigen : Triton Acquisition of Clinigen	05/04/22	PU
Form 8.3 - AXA INVESTMENT MANAGERS: Clinigen Group Plc	04/04/22	AQ
Form 8.3 - [Clinigen Group plc - 28 03 2022] - (CGWL)	29/03/22	AQ

Aucun résultat pour cette recherche